Financial Contrast: Trinity Biotech (NASDAQ:TRIB) and Envista (NYSE:NVST)

Trinity Biotech (NASDAQ:TRIB) and Envista (NYSE:NVST) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Profitability

This table compares Trinity Biotech and Envista’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
Envista	3.33%	7.88%	4.33%

Institutional and Insider Ownership

79.0% of Trinity Biotech shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by insiders. Comparatively, 1.0% of Envista shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Trinity Biotech and Envista”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.78 million	0.14	-$37.38 million	($44.26)	-0.17
Envista	$2.72 billion	1.51	$47.00 million	$0.58	43.98

Envista has higher revenue and earnings than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Trinity Biotech has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Envista has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Trinity Biotech and Envista, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1	0	0	0	1.00
Envista	0	8	7	1	2.56

Envista has a consensus target price of $29.71, suggesting a potential upside of 16.48%. Given Envista’s stronger consensus rating and higher possible upside, analysts plainly believe Envista is more favorable than Trinity Biotech.

Summary

Envista beats Trinity Biotech on 13 of the 15 factors compared between the two stocks.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.